In India, the country with the world's largest burden of tuberculosis (TB), most patients first seek 3 care in the private healthcare sector, which is fragmented and unregulated. Ongoing initiatives 4 are demonstrating effective approaches for engaging with this sector, and form a central part of 5 India's recent National Strategic Plan: here we aimed to address their potential impact on TB 6 transmission in urban settings, when taken to scale. We developed a mathematical model of TB 7 transmission dynamics, calibrated to urban populations in Mumbai and Patna, two major cities 8 in India where pilot interventions are currently ongoing.
6
medicine; (iv) and private, 'less-than-fully-qualified' (LTFQ) providers with other medical 1 qualifications, or none at all.
3
We used data from community-based patient pathway surveys, recently conducted in Mumbai 4 (76 TB patients and 196 patient-provider interactions) and Patna (64 TB patients and 121 5 patient-provider interactions), and described in detail elsewhere 11, 27 . In brief, individuals in the 6 community, who had been on TB treatment within the preceding 6 months, were administered 7 an in-depth interview, to identify the sequence and types of providers that each patient visited 8 before their TB diagnosis. Although subject to the usual limitations of patient recall 28 , this 9 community-based survey has nonetheless cast unprecedented light on the careseeking patterns 10 in these urban slum settings 11 .
12
A patient's contact with a given provider may last several days, sometimes weeks: this process 13 ends either when the provider eventually suspects and confirms TB, or when the patient drops 14 out to visit an alternative provider. Here, we model this combination of behaviours using 15 independent, competing exponential hazards, taking both to be specific to the type of provider Patna separately, we used the pathway survey data to estimate the hazard rates 
19
We also used this data to estimate the role of different provider types in the careseeking 20 pathway, in particular: the proportions of patients visiting each type of provider on the first 21 careseeking attempt, and the corresponding proportions on subsequent visits, conditional on the type of provider last seen. We used the Expectation-Maximisation algorithm as a systematic 23 approach for estimating rates and uncertainty (see supporting information for further details).
25
For parameters related to the treatment cascade (the proportion of TB diagnoses initiating and 26 completing treatment), we draw from a recent systematic review for the public sector 29 . In the 27 absence of systematic evidence for private providers, we incorporate plausible uncertainty 28 distributions for these parameters (Table S2 , supporting information).
30
Simulating impact 31 32 In both Mumbai and Patna, evidence suggests a marked heterogeneity amongst providers, with 33 certain specialist providers handling a substantially higher TB caseload than others. While this 34 suggests important opportunities for efficiency, by 'targeting' such providers, in the present 35 work, for simplicity we chose instead to measure PPSA 'coverage' from a patient perspective: 36 that is, the proportion of patient-provider interactions that involve a PPSA-engaged provider.
37
Thus, for example, we present a 75% 'coverage' in the understanding that -in practice -this 38 could be brought about by recruiting fewer than 75% of providers, in a targeted way. 7 1 For a given PPSA coverage, we simulated cumulative TB incidence and mortality between 2018 2 and 2025. We then estimated the TB cases and deaths averted, relative to a 'no-PPSA' 3 baseline, with the standard of TB care in public and private sectors projected forward without 4 change. We simulated two types of PPSA: an 'accurate diagnostic' scenario in which engaged 5 providers have diagnostic accuracy equal to those of the public sector, and a 'timely diagnostic' 6 scenario which, as well as accurate diagnosis, additionally encouraged private providers to 7 conduct a diagnostic test as early as possible (whether for TB or not). Note that, in both cases, 8 treatment outcomes were also assumed to be improved to the level of the public sector.
10

Uncertainty
12
We used a Bayesian melding procedure 30 to capture uncertainty in the epidemiological and 13 pathway inputs described above, as well as in other input parameters in the model (see 14 uncertainty ranges in tables S2, S3, supporting information). In brief, this procedure yields 15 100,000 parameter sets that, in ensemble, capture simultaneously the uncertainty in the 16 parameter inputs, and in the data. Projecting the epidemiological impact of a PPSA from each of 17 these parameter sets, under given scenarios for PPSA coverage, we then calculated the central 18 estimate and uncertainty in impact by calculating the 2.5 th , 50 th and 97.5 th percentiles in the 19 outcomes of interest (lives saved, percent cases averted). We refer to these uncertainty 20 intervals as 'credible intervals' (CrI) to distinguish them from the 'confidence intervals' arising 
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The model includes several different parameters (including epidemiological inputs). To identify 25 those parameters that are most important for model findings, we performed a multivariate 26 sensitivity analysis on the output of the Bayesian analysis described above. In particular, we 27 examined which model inputs accounted for the greatest amount of uncertainty in model 28 outputs: that is, the inputs that are most influential in the precision of the model output. To do 29 this we selected, as a model output, the percent cases averted by a PPSA intervention at 75% 30 coverage under the 'timely diagnostic' scenario described above, in both cities. We computed 31 the partial rank correlation coefficient (PRCC) between this output and each of the model 32 parameters: in brief, the PRCC quantifies the correlation between a given model input and the 33 model output, when variance in all other parameters has been accounted for. Those model 34 inputs expressing the greatest PRCC are those to which the model is most sensitive.
36
As well as this parameter uncertainty, we additionally tested the model sensitivity to two forms (for example if bacillary load rises with symptom severity), or decrease (for example if TB 1 patients exhaust their closest contacts as opportunities for infection), with implications for the 2 transmission that a PPSA could impact 31 . To capture these scenarios in a simple way, we 3 assumed that infectivity during the patient delay in Figure 1A is k times that during the 4 diagnostic delay. We tested sensitivity of model findings to k. (ii) Second, the PPSA we have 5 modelled is a combination of interventions, each involving different indicators for the quality of 6 TB care in the private sector. To examine the most important, we simulated a 'partial' PPSA that 7 could implement improvements in all but one of the indicators for quality of care. We recorded 8 the resulting drop in impact (percent cases averted), relative to a 'full' PPSA, and repeated this 9 analysis for each of the indicators involved. Figure S1 in the appendix (see also Table S3 ). For example, chemists play a stronger role in first careseeking in Patna than in Mumbai, while for 19 formally qualified providers the converse is the case. These differences underline the potential 20 heterogeneity in healthcare settings across India. 
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Results
13
22
24
Such an intervention is focused on improving diagnostic accuracy and treatment outcomes in 25 the private sector, without addressing the promptness with which a provider offers a diagnosis.
26
A PPSA of this scale would reduce cumulative TB incidence by 8.5% (95% CrI 4.2 -15.6%) 27 over the next ten years. There is a stronger impact on MDR-TB, with a reduction of 21.2% (95%
28
CrI 13.0 -32.5%) in cumulative incidence. Further, a PPSA of this scale could have a 29 substantial effect on TB mortality, reducing TB deaths by 21.7% (95% CrI 10.6 -35.0%).
31
If providers are additionally encouraged to order a diagnostic test as early as possible (i.e. a
32
'timely diagnosis' scenario to pre-empt patient dropout), PPSA impact increases substantially, to 33 an incidence reduction of 21.4% (95% CrI 11.1 -32.7%) and a mortality reduction of 38.1%
34
(95% CrI 20.0 -55.1%). Figure S2 (supporting information) shows similar, corresponding estimates for the patient and diagnostic delays illustrated in Fig.1 . As illustrated in Fig.4 , while 1 the simulated diagnostic delay is consistent with the 1 month estimated in previous analysis 8, 11 , Figure S4 in the appendix shows the potential epidemiological impact of a PPSA that is 5 enhanced by measures to shorten the patient delay; below we discuss possible examples of 6 such measures. 7 8 Figure 5 shows the results of parameter sensitivity analysis, in which we quantified the influence 9 of each model input against 'simulated impact', the latter measured as the percent cases 10 averted by a PPSA at 75% coverage in both Mumbai and Patna (corresponding to the green 11 shaded region in Figure 3 ). Figure 5 illustrates the importance of epidemiological inputs, for this 12 output. In both cities, the assumed prevalence and ARTI are the model inputs accounting for the 13 greatest amount of output uncertainty. Where the true value of prevalence in either city lies 14 towards the lower end of the assumed range, the percent cases averted approaches the upper 15 end of the uncertainty illustrated in Figure 3 , and vice versa for ARTI. In both settings the levels also a leading factor; remaining parameters, to which the model is less sensitive, depend on the 18 local conditions in both of these settings.
20
In addition to addressing parameter uncertainty we finally conducted sensitivity analysis to some 21 underlying assumptions. First, as described above, we allowed for differential infectiousness in 22 the two stages of delay shown in Figure 4 . Figure 6A shows results for the percent cases 
27
Second, we examined the sensitivity of projected impact to the assumption that all PPSA 28 activities are performed effectively. We aimed to identify which activities accounted for most of 29 the impact shown in Figure 3 Figure S1 , these results highlight how intervention priorities in different cities may 33 need to be tailored to the local conditions.
35
Discussion
37
Engaging with India's vast, fragmented private healthcare sector is a key step in enhancing TB 38 control in India. Our work adds to other modelling studies capturing the role of the private sector 39 in TB care in India, including a multi-model comparison examining packages of interventions in 10 the context of the End TB goals 23 , and the potential impact of implementing molecular 1 diagnostics in the private sector 21 . A strength of the current work is that it is informed by unique, 2 detailed patient pathway data from Mumbai and Patna. This data enables us to analyse the 3 relative importance of the different delays illustrated in Figure 1 , to a greater extent than in 4 previous work.
6
Our findings illustrate that a PPSA taken to scale in urban settings, such as Mumbai and Patna, 7 could have a meaningful impact on TB burden ( Fig.3, Fig.S3 ). Improved diagnosis and 8 treatment adherence could strongly reduce TB mortality. Moreover, the use of rapid molecular 9 tests in the private sector could have strong implications for MDR-TB: by facilitating the early 10 recognition of drug sensitivity status, such measures could turn a growing drug resistance 11 epidemic into a diminishing one ( Fig.3B , blue vs green curves).
13
Nonetheless, in terms of overall TB burden, our results suggest that engaging the private sector 14 alone will not be enough to meet the country's aspirations for TB elimination. Rather, such 
24
We note that this latter result is not directly measured, but inferred through reconciling ARTI and 25 prevalence in the model. Previous studies have approached patient and diagnostic delays 26 through retrospective patient interviews in various settings in India: a recent meta-analysis of 27 these studies 8 found a median patient delay of around 18 days. To our knowledge there is no 28 other independent, direct evidence for the 'true' patient delay. Nonetheless, there are some 29 notable comparisons in a recent TB prevalence survey in Gujarat state. Of the bacteriologically 30 positive TB cases, only 28% had sought care for their symptoms, including 11% that were on 31 TB treatment 33 . Although cross-sectional, these survey findings appear consistent with the 32 picture of substantial transmission occurring independently of the 'diagnostic delay'.
34
There are several possible reasons for these discrepancies between model and prevalence 35 survey findings on the one hand, and patient interviews on the other. For example, in urban 36 areas with poor air quality, prolonged cough is a common symptom: TB patients may tend to 37 visit a provider when their symptoms become more advanced (e.g. fever), ultimately reporting 38 only the duration of these more developed symptoms. Alternatively, the patient delay may truly be as short as 18 days, but only amongst those patients who seek care: there may remain a 1 patient population who never contact the healthcare system, for example due to the opportunity 2 costs of doing so. These factors may differ by region in India, as well as by gender and 3 urban/rural setting. As illustrated by Fig.S4 , mitigating these factors could maximize the impact 4 of a PPSA.
6
Approaches towards mitigating these factors could involve active case-finding (ACF) 34 . India's 7 recent National Strategic Plan underlines the potential importance of ACF in risk groups such as 8 urban slums 16 , while recent work in Viet Nam has also demonstrated the potential value of 9 screening close contacts of diagnosed TB cases, together with longitudinal followup of these 10 contacts 35 . However, it is also possible for the patient delay to be impacted by measures to 11 improve the demand for TB services; for example, social protection mechanisms 36 could have 12 the secondary effects of encouraging TB symptomatics to come forward for care 37 . Such effects 13 are currently hypothetical, and present an important evidence gap for future studies to address.
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As with any modelling approach, our model has several limitations to note. First, it takes a
In future, better data on careseeking and the quality of care with respect to these factors would support a more refined approach incorporating these factors. Second, our work concentrates on 19 two major cities in India, informed by the available, community-based studies on careseeking 20 pathways. Further work, deploying such surveys more broadly, should explore to what extent 21 these findings may be generalized to other cities India; one potentially important factor is the greater HIV burden in states like Andhra Pradesh 3 . Moreover, this work does not address 23 potential impact in rural settings. Indeed, recent work has highlighted the phenomenon of TB 24 prevalence being higher in rural areas than urban 38 , suggesting even longer delays before 25 initiation of appropriate TB treatment: there is therefore a pressing need for a better 26 understanding of healthcare utilisation in these settings. Third, we have made several 27 simplifying assumptions on provider behaviour, namely that 'engaged' providers would show the 28 same standard of care as in the public sector. As noted above, it is promising that the PPSA 29 pilots have shown a dramatic increase in the number of TB cases being notified 1,3 : ongoing 30 data collection during the pilots will cast light on the extent to which the quality of TB care has 31 been improved. Lastly, these results are quite sensitive to underlying assumptions about 32 prevalence and ARTI, as well as to transmission over the course of illness. If more transmission 33 is occurring at later stages of illness, then private provider engagement could more effectively 34 interrupt transmission and avert twice as many cases as our baseline uninformed assumption of
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In summary, private sector engagement is a key foundation for managing TB in India. In 1 addition to its direct benefit to TB patients, an engaged private sector will also enable the The authors have no competing interests that might be perceived to influence the results and/or 3 discussion reported in this paper. Table S2 ). The 'bubble' in orange denotes the sequence of providers that a patient visits before receiving a TB diagnosis. Here, we distinguish . Components of the mean infectious period, i.e. the duration from the start of active disease to treatment initiation, death or self cure. Simulated in the absence of any PPSA intervention. The light grey region shows the simulated patient delay, while the dark grey region shows the delay in diagnosis (i.e. from first provider visit). Error bars in blue and red show the uncertainty in these estimates, respectively. The patient delay estimate is driven by prevalence and ARTI, while the diagnostic delay estimate is driven by the process illustrated in Fig.1B . A PPSA addressing only patient behaviour would impact only the dark grey regions.
Figure 5. Multivariate sensitivity analysis of model inputs (parameters and data).
Bars show the partial rank correlation coefficient (PRCC) between each model input and a selected output: 'simulated impact', or the percent cases averted by a PPSA acting at 75% coverage, with accurate and early diagnosis. Figures show that in both Mumbai and Patna, the two model inputs to which simulated impact is most sensitive are the prevalence and ARTI. Prevalence has a negative partial rank correlation with impact: that is, lower values of prevalence are associated with higher levels of impact, and vice versa for ARTI. Note that the combined effect of uncertainty in all of these parameters corresponds to the full uncertainty range illustrated in Figure 3A , green shaded region. This range indicates the maximum extent to which model outputs could diverge from central estimates, subject to the assumed uncertainty ranges in model inputs. . The x-axis shows a range of scenarios for the infectivity during the patient delay, relative to that during the diagnostic delay. (B, C) Identifying key elements of private provider behaviour. The figures show the drop in overall impact that results, when a PPSA that fails to improve the provider behaviour shown (while addressing all remaining provider behaviours). For clarity, plots show only the four most important factors in each setting. Bar colours denote different provider types, as shown in the right-hand legen
Model specification
The model is governed by the following equations (see table S1 for definitions of state   variables, and table S2 for parameter definitions and sources). First, for the states prior to a TB patient's first visit to a provider, we have: where the subscript s denotes the infecting strain (with values 0,1 denoting drug-susceptible and drug resistant TB, respectively). The parameter c is the rate of careseeking, its inverse representing the average patient delay before first presentation for care.
Upon presenting for care, we assume that a proportion pr of patient visit a provider of type r (denoting the public sector; FQ providers; LTFQ providers; and chemists -see table S1).
We have, for those awaiting diagnosis with provider type r and infected with strain s: As described in the main text, a patient-provider interaction may last days to weeks. This stage ends either when the provider finally offers a diagnosis (whether correctly for TB or otherwise), or when the patient leaves the provider, to seek care elsewhere. Here, we model these two endpoints through competing hazards of offering a diagnosis (R -), versus the patient leaving the provider (ℎ -). As described below, these rates are estimated from the patient pathway surveys conducted in Mumbai and Patna 1 .
Ṁ
We assume that a proportion Tof TB patients visiting provider type r successfully initiate TB treatment (the remainder constituting missed diagnosis as well as initial loss to followup, covered below). For those initiating first-line treatment, it is convenient to specify equations separately by drug-susceptible (s = 0) and drug-resistant (s = 1) status. Thus we have, for drug-susceptible TB:
where [ -is the per-capita rate of default from first-line treatment with provider type r and \ represents the per-capita hazard of acquisition of multi-drug-resistance while on first-line TB treatment, only applicable to drug-sensitive TB. We assume that those defaulting from treatment are bacteriologically negative, but have an elevated risk of relapse, in comparison with those who have successfully completed treatment. The relevant compartments are discussed below.
For drug-resistant TB on first-line treatment, we have:
where _ -is the proportion of TB patients presenting to a provider of type r who undergo drug sensitivity testing at the point of TB diagnosis. Those who have recovered from disease include patients who have completed treatment; those who have defaulted from treatment; and those who have recovered spontaneously.
We assume the latter two to have an elevated risk of relapse compared to the former, in the two years following recovery. Following this period, remaining recovered individuals stabilize in their relapse risk. Thus we have, for the 'high' and 'low' relapse risk compartments, respectively: Finally, for the forces-of-infection 7 V , 7^ for DS-and DR-TB respectively, we have:
and likewise for 7^, but with ! "#$ in place of !.
Patient pathways
We adopted four different categories of provider: (i) those in the public sector (DOTS facilities);
(ii) private chemists; (iii) private, 'fully qualified' (FQ) providers with qualifications in allopathic medicine; (iv) and private, 'less-than-fully-qualified' (LTFQ) providers with other medical qualifications, or none at all.
We used data from community-based patient pathway surveys, recently conducted in Mumbai (76 TB patients and 196 patient-provider interactions) and Patna (64 TB patients and 121 patient-provider interactions), and described in detail elsewhere 1 . In brief, individuals in the community, who had been on TB treatment within the preceding 6 months, were administered an in-depth interview, to identify the sequence and types of providers that each patient visited before their TB diagnosis.
A patient's contact with a given provider may last several days, sometimes weeks: this process ends either when the provider eventually makes a diagnosis, or when the patient drops out to visit an alternative provider. Here, we model this combination of behaviours using independent, competing exponential hazards with rates % #&'()*+&+ noR % #-*.*/0 ,specific to the type of provider involved (public, FQ, LTFQ or chemist). Figure 1B , and we estimate the accuracy of diagnosis of each type of provider from the data. We also model the role of different provider types in the careseeking pathway, in particular: the proportions of patients visiting each type of provider on the first careseeking attempt, and the corresponding proportions on subsequent visits, conditional on the type of provider last seen. 30 of the 196 patient-provider interactions in Mumbai, and 11 of the 121 patient-provider interactions in Patna, are such that the providers consulted are private, however, their qualifications, and hence their types (LTFQ/FQ), are missing. We let each missing provider type be represented by an unknown binary variable. Since the model parameters are specific to the provider type, the expression for the likelihood of the pathways data as a function of the model parameters also involves the missing binary variables. We use the iterative algorithm Expectation Maximization (EM) to obtain the maximum likelihood estimates of parameters. Each iteration involves two steps: E-
Step: Finding the expectation of the log likelihood function, over the distribution of the missing binary variables conditioned on the observed data, under an initial estimate of the parameters, and M-Step: Maximizing the expectation of the log likelihood function to obtain a revised estimate of parameters. The revised estimate is then used as an initial estimate for the E-Step, and the process continues until the values of the maximum expectation of the log likelihood converge within a specified tolerance. The associated variance-covariance matrix of the estimates is approximated as the inverse of the observed Fisher Information Matrix, which is equal to the difference of the negative of the expectation of the Hessian matrix of the complete data log likelihood function, conditioned on the incomplete data and the expectation of the square of gradient of complete data log-likelihood function, conditioned on the incomplete data; evaluated at the final iteration of the EM algorithm.
For parameters related to the treatment cascade (the proportion of TB diagnoses initiating and completing treatment), we draw from a recent systematic review for the public sector 2 . In the absence of systematic evidence for private providers, we incorporate plausible uncertainty distributions for these parameters (Table S2 ).
Model calibration and propagating uncertainty
We denote by | the vector of input parameters, including !, ! "#$ , I, and other model inputs subject to uncertainty. For a given country, and a given parameter set |, we initially simulated the model to equilibrium in the absence of the public sector (e.g. as in ref. 3 ) and
MDR-TB, to capture the early history of the TB epidemic. Subsequently allowing population growth, we initiated the emergence and spread of DR-TB from 1980. We also captured the expansion of the public sector as a linear increase in N V during the years of RNTCP scaleup, i.e. from 1997 to 2006 4 . By combining these processes, we determined model projections for calibration targets (prevalence, ARTI and percent of incident TB cases being drug-resistant), assumed to apply in 2017.
To compare these model projections with data D, we defined the posterior density }(|) as:
where 9 is the likelihood of the data D given | and P is the joint prior distribution for |. For P, we took independent uniform distributions over the ranges shown in table S2 (taking +/-20% of the point values where no ranges are shown). The likelihood 9 is constructed as follows.
We fitted a log-normal distribution to prevalence: in particular, we determined the mean and variance of this distribution in order for the 2.5 th , 50 th and 97.5 th percentiles to match respectively the lower, mid and upper ranges of prevalence estimates. We write U (Ç-ÉÑ) (•) for the probability density thus obtained. Likewise, we write U (Ü$Ká) (•), U (."#$) (•) for the inferred probability densities corresponding respectively to prevalence and the proportion of incident TB that is MDR in year t. Then we have, for the overall likelihood:
where, for example, äAãG(|) is the simulated value of incidence in 2017 given parameters |, and likewise for the other functions of | in the expression above. In practice we compute the logarithm of }(|), thus taking the sum of the logarithms of each of the terms shown above.
With }(|) thus defined, we sampled the posterior density using a Markov Chain Monte Carlo approach. In brief, this approach implements a random walk through the space of parameter values | to obtain an unbiased sample of the posterior density. We implemented the Notes: (a) As the pathway data does not have information about the quality of TB care, we have only partitioned these parameters by public vs private sector, assuming all 'private' parameters to apply to FQ, LTFQ providers alike. (b) See Table 2 for parameters relating to diagnosis, all inferred from the pathway surveys. (c) With the use of GeneXpert as a diagnostic tool, we assume this rises to 0.9 under a PPSA, with drug-resistant patients being referred to the public sector. 
